Theolytics
Cell & Gene Therapy
Overview
Our Adenovo™ platform and 100-million-variant library move us from discovery to impact. With THEO-260 as our lead programme, our world-class team is applying world-leading science to expand access to innovative therapies that promise lasting benefit.
Official records
Funding and backers
Team
51-200
employees, estimated range
Grants
$5.8M
1 grant · CORDIS
Backers
5
Epidarex Capital, M Ventures
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 1
Won a grant $5.8M · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jun 2026 | $5.8M | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Benefits platform for cell and gene therapies designed to provide sustainable access to life-saving medicines.
Kytopen is accelerating access to the next generation of cell therapies through scalable genome engineering by solving manufacturing…
Where regenerative medicine meets uncompromising cosmetic science to create evidence-based skincare worth the hype.
Skyline Therapeutics is a fully integrated gene therapy company dedicated to the discovery, development and delivery of innovative…
Immuneel is advancing access to breakthrough cancer therapies in India, for India and the world.. Cell, gene, and immunotherapies are…
Designer cell therapies for pets first and their people next.
Financials
Total raised
$5.8M
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2026 | $5.8M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Sound BioventuresVia a fund
Taiho VenturesVia a fund
Epidarex CapitalVia a fund
M VenturesVia a fund
Oxford Science EnterprisesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy - including THEO-260 in Advanced Ovarian Cancer - at Upcoming Investor and Scientific Events
Oxford, UK, September 16, 2026 - Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today an...
Read more
Report
Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy - including THEO-260 in Advanced Ovarian Cancer - at Upcoming Investor and Scientific Events
Oxford, UK, September 16, 2026 - Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that members of its senior leadership team will participate in a series of upcoming investor, partner
Read more
Report
Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies
Oxford UK, July 16th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces tha...
Read more
Report
Theolytics' Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stroma-rich tumoursUS trial (OCTOPOD-IP) is exploring safety and tolerability of intraperitone
Read more
Report
Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics' innovative science and strong clinical development pla
Read more
Report